RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Cidara Therapeutics Net Income 2024

Cidara Therapeutics Net Income

-2.68 M USD

Cidara Therapeutics Dividend yield

Ticker

CDTX

ISIN

US1717571079

WKN

A14R2R

In 2024, Cidara Therapeutics's profit amounted to -2.68 M USD, a -88.3% increase from the -22.93 M USD profit recorded in the previous year.

The Cidara Therapeutics Net Income history

YEARNET INCOME (undefined USD)
2029e58.16
2028e49.4
2027e15.91
2026e0.25
2025e-0.6
2024e-2.68
2023-22.93
2022-29.8
2021-42.47
2020-74.87
2019-41.09
2018-69.35
2017-55.73
2016-48.17
2015-32.19
2014-11.89
2013-1.34

Cidara Therapeutics Aktienanalyse

What does Cidara Therapeutics do?

Cidara Therapeutics Inc. is a biopharmaceutical company specializing in the development and marketing of innovative therapies for serious infectious diseases. The company was founded in 2013 and is headquartered in San Diego, California. The founders of Cidara Therapeutics Inc. aimed to develop a new class of antifungal drugs that are particularly effective against fungal infections. The underlying technology is based on the Cloudbreak® peptide platform, which allows for the production of drugs with improved efficacy and safety. The company also has research collaborations with leading scientists in the field of infectious diseases to advance the development of antibody therapy, vaccines, and other drugs. The business model of Cidara Therapeutics Inc. focuses on the development and marketing of innovative therapeutic products for unmet medical needs. The company has divided its products into three divisions: infectious diseases, oncology, and immunology. Cidara's product pipeline includes several innovative drugs that have shown efficacy in phase I and phase II clinical trials. The infectious diseases division initially focuses on the development of antifungal drugs for the treatment of Candida infections, which can be life-threatening for people with weakened immune systems. Cidara Therapeutics Inc. has already successfully completed a clinical trial for its lead product, rezafungin. Rezafungin is a long-acting, liposomal antifungal drug that enables a single dose for effective treatment of Candida infections. The oncology division focuses on the development of innovative immunotherapies that use the body's immune system to attack cancer cells. Cidara Therapeutics Inc. utilizes the Cloudbreak® platform technology to develop new drugs that specifically target certain types of cancer. The lead product in this pipeline is CD371, a monoclonal antibody targeting acute myeloid leukemia (AML). The immunology division focuses on developing therapeutics for autoimmune diseases that bring the body's immune system under medical control to reduce inflammation and damage to target organs. The lead product in this product line is Cloudbreak® immunomodulators, which specifically regulate immune responses and combat inflammation. Overall, Cidara Therapeutics Inc. is a promising company that focuses on the development and marketing of innovative drugs for high unmet medical needs. The company's diverse and well-balanced product pipelines in the areas of infectious diseases, oncology, and immunology demonstrate the great potential of this business model. With the advanced Cloudbreak® technology and the dedicated team, Cidara Therapeutics Inc. has the potential to take a global leadership role in drug development and save lives. Cidara Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Cidara Therapeutics's Profit Margins

The profit margins of Cidara Therapeutics represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Cidara Therapeutics's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Cidara Therapeutics's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Cidara Therapeutics's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Cidara Therapeutics’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Cidara Therapeutics Stock

How much profit has Cidara Therapeutics made this year?

Cidara Therapeutics has made -2.68 M USD this year.

How has the profit developed compared to last year?

The profit has increased by -88.3% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Cidara Therapeutics publish its earnings?

Cidara Therapeutics publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Cidara Therapeutics?

The profits of Cidara Therapeutics are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Cidara Therapeutics?

You can learn more about the earnings of Cidara Therapeutics by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Cidara Therapeutics pay?

Over the past 12 months, Cidara Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cidara Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Cidara Therapeutics?

The current dividend yield of Cidara Therapeutics is .

When does Cidara Therapeutics pay dividends?

Cidara Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cidara Therapeutics?

Cidara Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Cidara Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cidara Therapeutics located?

Cidara Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cidara Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cidara Therapeutics from 5/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/18/2024.

When did Cidara Therapeutics pay the last dividend?

The last dividend was paid out on 5/18/2024.

What was the dividend of Cidara Therapeutics in the year 2023?

In the year 2023, Cidara Therapeutics distributed 0 USD as dividends.

In which currency does Cidara Therapeutics pay out the dividend?

The dividends of Cidara Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Cidara Therapeutics

Our stock analysis for Cidara Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cidara Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.